DIRS.INFO The most relevant business & tech news

☆ Weight-loss drugs could stave off dementia, small study finds
▼ + stars: | 2024-07-30 | by ( Hilary Brueck | ) www.businessinsider.com time to read: +6 min

Today, a group of dementia researchers from the UK released some early results that suggest it's possible these trendy injections might also stall the progression of dementia. A daily injection for brain preservationIuliia Burmistrova/Getty ImagesFor the study, researchers spent a year tracking brain changes across 204 Alzheimer's patients with mild to moderate disease. "It sounds like it is worth pursuing a larger trial, but these results cannot demonstrate that liraglutide can protect against dementia." Experts have seen how dementia patients' brains get worse and worse at efficiently using glucose for energy as their disease progresses, but the calculus is always complicated. Bigger studies using more powerful GLP-1 drugs for dementia are already ongoing.

Persons: Stephen Evans, Jason Kirk, Quynh Nguyen, hadn't, Dr, Paul Edison, it's, Edison, Alzheimer's Organizations: Service, Alzheimer's Association International Conference, London School of Hygiene, Medicine, Science Media, Nikon, Imperial College London, Food and Drug Administration, Novo Nordisk Locations: Philadelphia, Novo

☆ Scientists say weight-loss drugs could protect our brains from dementia. Early results suggest they're onto something.
▼ + stars: | 2024-07-30 | by ( Hilary Brueck | ) www.businessinsider.com time to read: +6 min

☆ Older GLP-1 drug from Novo Nordisk may slow Alzheimer's disease progression by protecting the brain, study says
▼ + stars: | 2024-07-30 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +5 min

George Frey | ReutersAn older, once-daily drug for diabetes and obesity from Novo Nordisk called liraglutide may slow the progression of Alzheimer's disease by protecting patients' brains, according to data from a mid-stage trial released on Tuesday. Novo Nordisk sells liraglutide as a diabetes and obesity drug under the brand names Victoza and Saxenda, respectively. Alzheimer's disease often causes the brain to shrink as the illness progresses because crucial nerve cells break down and stop working properly. By 2050, the number of Alzheimer's patients is projected to rise to almost 13 million in the U.S. The ongoing EVOKE is examining semaglutide, the active ingredient in Wegovy and Ozempic, in nearly 2,000 Alzheimer's patients.

Persons: George Frey, Eli Lilly, liraglutide, Brian B, Bettencourt, Heather Snyder, Leqembi, Snyder, Dr, Paul Edison, Edison, Bobby Pugh, Bessie Pugh, Karen Pulfer Focht Organizations: Novo Nordisk Pharmaceutical, Reuters, Novo Nordisk, Imperial College London, Alzheimer's Association International Conference, Toronto Star, Getty, Alzheimer's Association, U.S, CNBC, Alzheimer's, Novo Nordisk's, Ave Locations: Provo , Utah, Danish, Philadelphia, Biogen, Novo, Bartlett , Tennessee, U.S

☆ Patients on Alzheimer's drug Leqembi see benefits over three years, Eisai study says
▼ + stars: | 2024-07-30 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +3 min

The newly FDA approved Alzheimer's treatment Leqembi is prepared at Abington Neurological Associates in Abington, PA., on Tuesday, November 7, 2023. The breakthrough Alzheimer's drug Leqembi slowed disease progression in patients over three years, demonstrating the need for them to stay on the treatment long term, according to new data released Tuesday by Japanese drugmaker Eisai. The study results on Leqembi, which Eisai shares with Biogen , also found that a patient's Alzheimer's disease worsens after they stop treatment. The results are a first glimpse at what Alzheimer's patients' future could look like on therapies such as Leqembi, which is currently taken twice a month through an infusion. By 2050, the number of Alzheimer's patients is projected to rise to almost 13 million in the U.S.

Persons: Lynn Kramer, Leqembi, Eisai, Kramer Organizations: FDA, Abington Neurological Associates, Biogen, CNBC, Alzheimer's Association International Conference, Alzheimer's Association Locations: Abington, Abington , PA, U.S, Philadelphia

☆ The 1 food you should eat for brain health — and why you can't replace it with supplements
▼ + stars: | 2024-07-26 | by ( Hilary Brueck | ) www.businessinsider.com time to read: +8 min

AdvertisementSherzai knows it's tempting to reach for a novel, quick-fix potion that promises to boost brain health, like a fancy supplement, an expensive gummy, or a new smoothie powder. Why chlorophyll from plants is more powerful than green juices and supplementsLots of chlorophyll on the table here. fcafotodigital/Getty ImagesWhen we eat green plants, we are consuming a green pigment molecule called chlorophyll, which helps plants photosynthesize — capturing solar rays and converting them into energy to grow. What we do know is that you can get the health benefits if you consume chlorophyll in its original packaging. Galina Oleksenko/Getty ImagesSherzai recommends incorporating more of the darkest green plants like spinach and kale into your diet when you can.

Persons: —, Dean Sherzai, Chicago —, Dean, Ayesha Sherzai, he's, Troy Magney, Davis, Magney, you'll, Kale, Galina Oleksenko, It's, Amber Flores, Flores Organizations: Service, National Institute, Aging, Business, University of California, UC Davis Locations: Chicago

☆ HRT use by younger women linked to dementia, study says. Experts disagree
▼ + stars: | 2023-06-28 | by ( Sandee Lamotte | ) edition.cnn.com time to read: +7 min

However, experts who treat and study menopause say the study is unable to draw a direct connection to later-life dementia and that the overall benefits of hormone replacement therapy, or HRT, far outweigh the risks for many patients. “One finding in the study was a link between dementia and the use of HRT for a very short time span, under a year. Researchers compared people with dementia who had used hormone therapy, even briefly, with those from the larger group who had not. The chance of being diagnosed with dementia went up with years spent on HRT, the study found. When women used 12 or more years of hormone therapy, the association with a diagnosis of dementia rose to 74%, Pourhadi said.

Persons: ”, Nelsan, Pauline Maki, David Curtis, Kejal, Kantarci, Andrea Lenzi, University of Rome La Sapienza, ” Pourhadi, Pourhadi, Maki, ” Maki, Susan Davis, Amanda Heslegrave, ” Heslegrave Organizations: CNN, Danish Dementia Research, Copenhagen University Hospital Rigshospitalet, University of Illinois, UCL Genetics Institute, University College London, Mayo Clinic, University of Rome La, University of Illinois’s Center for Research, Women’s, Monash University, Dementia Research Locations: Danish, Denmark, Chicago, neuroradiology, Rochester , Minnesota, Taiwan, Melbourne, Australia, London

☆ Study reveals how treating hearing loss could impact dementia risk
▼ + stars: | 2023-04-13 | by ( Madeline Holcombe | ) edition.cnn.com time to read: +5 min

CNN —Treating hearing loss could mean reducing the risk for dementia, according to a new study. Hearing loss may increase the risk for dementia, but using hearing aids lowered the risk so it’s similar to those without hearing loss, according to the study published Thursday in The Lancet. A 2020 Lancet commission on dementia prevention, intervention and care suggested hearing loss may be associated with around 8% of dementia cases, but this study found that the use of hearing aids reduced the risk to levels similar to people without hearing loss, the study said. “A recent study showed that only 15% of US adults with hearing loss use hearing aids,” De Sousa said. The Hearing Loss Association of America still supports multiple avenues for addressing hearing loss, Hamlin said.

☆ Putin took cancer drugs that warped his decision-making on Ukraine, Danish intel says, reviving disputed theories about his health
▼ + stars: | 2022-12-30 | by ( Joshua Zitser | ) www.businessinsider.com time to read: +4 min

A Danish intelligence official said Putin was taking thyroid-cancer drugs in February 2022. He told Danish media the drugs can cause "delusions of grandeur" and may have warped his thinking. The claim was reported by the Danish newspaper Berlingske based on an interview with the head of the Russia analysis team for its national defense intelligence agency, Forsvarets Efterretningstjeneste (FE). He told the newspaper that Putin was taking hormones to treat thyroid cancer in February 2022, and that it likely affected his mental capacity. The Danish official also spoke to Berlingske in guarded language, asserting that reports of Putin having had thyroid cancer were "definitely a good bet."

☆ Experimental drug appears to slow progression of Alzheimer’s disease in clinical trial but raises safety concerns
▼ + stars: | 2022-11-29 | by ( Jacqueline Howard | ) edition.cnn.com time to read: +11 min

It involved 1,795 adults, ages 50 to 90, with mild cognitive impairment due to early Alzheimer’s disease or mild Alzheimer’s disease-related dementia. Such a score is consistent with early Alzheimer’s disease, with a higher number associated with more cognitive impairment. By 18 months, the CDR-SB score went up 1.21 points in the lecanemab group, compared with 1.66 in the placebo group. Overall, there were serious adverse events in 14% of the lecanemab group and 11.3% of the placebo group. The researchers also wrote that about 0.7% of participants in the lecanemab group and 0.8% of those in the placebo group died, corresponding to six deaths documented in the lecanemab group and seven in the placebo group.

Search resuls for: "Dementia Research"

9 mentions found